The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study
Phase of Trial: Phase II/III
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Armodafinil (Primary)
- Indications Cognition disorders; Multiple sclerosis
- Focus Therapeutic Use
- 01 Sep 2012 Results published in Cognitive and Behavioral Neurology.
- 01 Sep 2012 Status changed from recruiting to completed based on results in Cognitive and Behavioural Neurology.
- 09 Feb 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.